Results 41 to 50 of about 3,942,933 (245)

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.

, 2015
RAF and MEK inhibitors are effective in BRAF-mutant melanoma but not in BRAF-mutant colorectal cancer. To gain additional insights into this difference, we performed a genome-scale pooled shRNA enhancer screen in a BRAF-mutant, RAF inhibitor-resistant ...
Root, DE, Garraway, LA, Whittaker, SR, Luo, F, Cowley, GS, Wagner, S   +5 more
core   +1 more source

Identification and functional analysis of N6‐methyladenine (m6A)‐related lncRNA across 33 cancer types

Cancer Medicine, 2023
Background N6‐methyladenosine (m6A) plays an essential role in tumorigenesis and cancer progression. Long noncoding RNAs (lncRNAs) are discovered to be important targets of m6A modification, and they play fundamental roles in diverse biological processes.
Dahua Xu, Zhizhou Xu, Xiaoman Bi, Jiale Cai, Meng Cao, Dehua Zheng, Liyang Chen, Peihu Li, Hong Wang, Deng Wu, Jun Yang, Kongning Li   +11 more
doaj   +1 more source

Cancer‐associated mutations in endometriosis reframe a benign disease through molecular oncology

Molecular Oncology, EarlyView.
This review aims to comprehensively analyse cancer‐associated somatic mutations (CAMs) present in endometriotic lesions, emphasizing their biological roles, spatial distribution and implications for translational applications in medicine. By contextualizing a benign state within a genomic framework, this analysis seeks to establish its value as a ...
Clarissa Mujacic, Maria Concetta Vitale, Rita Siino, Emilia Di Giovanni, Carla Ferrante Bannera, Enrico Di Marco, Andrea Gottardo, Tancredi Didier Bazan Russo, Nadia Barraco, Alessandro Perez, Valerio Gristina, Antonio Galvano, Giuseppe Badalamenti, Antonio Russo, Viviana Bazan, Lorena Incorvaia   +15 more
wiley   +1 more source

National Aboriginal and Torres Strait Islander cancer framework 2015 [PDF]

, 2015
Overview The National Aboriginal and Torres Strait Islander Cancer Framework (the Framework) provides high-level guidance and direction for the many individuals, communities, organisations and governments whose combined efforts are required to address ...
Cancer Australia
core  

T cell receptors equipped with ICOS provide T cells with durable anti-tumor response

Molecular Cancer
Treatment with adoptively transferred T cells is challenged by limited longevity of therapeutic cells within tumors. To enhance the durability of anti-tumor T cell products, we have created T cell receptors (TCRs) with built-in co-stimulatory molecules ...
Alexandre Marraffa, Cor Berrevoets, Margherita Mosiello, Rui M.L. Coelho, Daphne Roelofs, Mandy van Brakel, Rebecca Wijers, Kim Kroese, Marlies J.W. Peeters, Willem A. Dik, Andre Kunert, Rachel J.M. Abbott, Dora Hammerl, Christopher Schliehe, Reno Debets   +14 more
doaj   +1 more source

MET transcriptional regulator/serine peptidase inhibitor kunitz type 1 panel operating through HGF/c‐MET axis as a prognostic signature in pan‐cancer

Cancer Medicine, 2021
Dysregulations in transcription factors (TFs) and their genetic products play important roles in tumorigenesis, tumor progression and metastasis. However, prognostic value of the transcriptional regulatory networks in different cancers has not been ...
Yi Xiang, Bishan Liang, Yu Jiang, Fei Sun, Yang Zhao, Qijing Wu, Xingbin Hu, Yajing Liu, Qiong Huang, Wangjun Liao, Zhiqi Yao, Shaowei Li, Min Shi   +12 more
doaj   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium.

, 2007
Association studies in large series of breast cancer patients can be used to identify single-nucleotide polymorphisms (SNP) contributing to breast cancer susceptibility.
Pharoah, Paul DP, Hogervorst, Frans BL, Dunning, Alison M, Nevanlinna, Heli A, Blomqvist, Carl,, Tommiska, Johanna, Healey, Catherine S, Pharoah, Paul D P, Tollenaar, Rob A E M, Reincke, Scarlett, Peto, Julian, Blomqvist, Carl, Van't Veer, Laura J, Johnson, Nichola, Fletcher, Olivia, Tollenaar, Rob AEM, Broeks, Annegien, Schmidt, Marjanka K, Braaf, Linde M, Hogervorst, Frans B L, Breast Cancer Association Consortium, Easton, Douglas F, Dörk, Thilo   +22 more
core   +1 more source

Targeting the p300/CBP Axis in Lethal Prostate Cancer.

, 2021
Resistance to androgen receptor (AR) blockade in castration-resistant prostate cancer (CRPC) is associated with sustained AR signaling, including through alternative splicing of AR (AR-SV).
Crespo, M, Sharp, A, Rekowski, J, McNair, C, Swain, A, Carreira, S, de Bono, JS, Prosser, A, Onions, S, Ning, J, Raja, M, Gurel, B, West, W, Neeb, AJ, Young, B, Lane, J, Gil, VS, Paoletta, S, Worthington, J, Pereira, R, Schiewer, MJ, Yuan, W, Brooks, N, Thomson, S, Pegg, N, SU2C/PCF International Prostate Cancer Dream Team,, Taddei, D, Smyth, D, Chand, SN, Shannon, J, Knudsen, KE, Ferreira, A, Riisnaes, R, Bogdan, D, Miranda, S, Tunariu, N, Brown, R, Figueiredo, I, Harbottle, GW, Welti, J, Pal, A   +40 more
core   +1 more source